| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Abuse-Deterrent Opioid Formulations: Pharmacokinetic and Pharmacodynamic Considerations
|
Walter, Carmen
|
|
2015
|
|
7 |
p. 751-767
|
artikel
|
| 2 |
A Comprehensive Review of Novel Drug–Disease Models in Diabetes Drug Development
|
Gaitonde, Puneet
|
|
2016
|
|
7 |
p. 769-788
|
artikel
|
| 3 |
A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis
|
van Beek, Stijn W.
|
|
|
|
7 |
p. 943-953
|
artikel
|
| 4 |
A Novel Maturation Function for Clearance of the Cytochrome P450 3A Substrate Midazolam from Preterm Neonates to Adults
|
Ince, Ibrahim
|
|
2013
|
|
7 |
p. 555-565
|
artikel
|
| 5 |
Antifungal Dosing in Critically Ill Patients on Extracorporeal Membrane Oxygenation
|
Lyster, Haifa
|
|
|
|
7 |
p. 931-942
|
artikel
|
| 6 |
A Population Pharmacokinetic Model of Pentobarbital for Children with Status Epilepticus and Severe Traumatic Brain Injury
|
Ketharanathan, Naomi
|
|
|
|
7 |
p. 1011-1022
|
artikel
|
| 7 |
A Prospective Population Pharmacokinetic Study on Morphine Metabolism in Cancer Patients
|
Oosten, Astrid W.
|
|
2016
|
|
7 |
p. 733-746
|
artikel
|
| 8 |
A Re-evaluation and Validation of Ontogeny Functions for Cytochrome P450 1A2 and 3A4 Based on In Vivo Data
|
Salem, Farzaneh
|
|
2014
|
|
7 |
p. 625-636
|
artikel
|
| 9 |
A Review of the Methods and Associated Mathematical Models Used in the Measurement of Fat-Free Mass
|
Sinha, Jaydeep
|
|
2018
|
|
7 |
p. 781-795
|
artikel
|
| 10 |
Authors’ Reply to Castello-Bridoux et al.: “Comment on Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?”
|
Concordet, Didier
|
|
2019
|
|
7 |
p. 973-975
|
artikel
|
| 11 |
Authors’ Reply to Castello-Bridoux et al.: “Comment on Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?”
|
Concordet, Didier
|
|
|
|
7 |
p. 973-975
|
artikel
|
| 12 |
Authors’ Reply to Coste et al.: “Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?”
|
Concordet, Didier
|
|
2019
|
|
7 |
p. 967-968
|
artikel
|
| 13 |
Authors’ Reply to Coste et al.: “Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?”
|
Concordet, Didier
|
|
|
|
7 |
p. 967-968
|
artikel
|
| 14 |
Authors’ Reply to Nicolas: “Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?”
|
Concordet, Didier
|
|
2019
|
|
7 |
p. 961-963
|
artikel
|
| 15 |
Authors’ Reply to Nicolas: “Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?”
|
Concordet, Didier
|
|
|
|
7 |
p. 961-963
|
artikel
|
| 16 |
Author’s Reply to Reith: “Morbidly Obese Patients Exhibit Increased CYP2E1-Mediated Oxidation of Acetaminophen”
|
Rongen, Anne van
|
|
2018
|
|
7 |
p. 897-899
|
artikel
|
| 17 |
Author’s Reply to Trechot: “Comment on Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?”
|
Concordet, Didier
|
|
2019
|
|
7 |
p. 979-980
|
artikel
|
| 18 |
Author’s Reply to Trechot: “Comment on Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?”
|
Concordet, Didier
|
|
|
|
7 |
p. 979-980
|
artikel
|
| 19 |
Avelumab Dose Selection for Clinical Studies in Pediatric Patients with Solid Tumors
|
Vugmeyster, Yulia
|
|
|
|
7 |
p. 985-995
|
artikel
|
| 20 |
Bioequivalence of Intravenous Alteplase from Two Different Manufacturing Processes in Healthy Male Volunteers: Results from a Two-Stage, Adaptive-Design Study
|
Glund, Stephan
|
|
|
|
7 |
p. 1023-1030
|
artikel
|
| 21 |
Clinical and Translational Pharmacology Considerations for Anti-infectives Approved Under the FDA Animal Rule
|
Temrikar, Zaid H.
|
|
|
|
7 |
p. 943-953
|
artikel
|
| 22 |
Clinical Impact of the Adaptation of Initial Tacrolimus Dosing to the CYP3A5 Genotype After Kidney Transplantation: Systematic Review and Meta-Analysis of Randomized Controlled Trials
|
Yang, Hui
|
|
|
|
7 |
p. 877-885
|
artikel
|
| 23 |
Clinical Micro-Dose Studies to Explore the Human Pharmacokinetics of Four Selective Inhibitors of Human Nav1.7 Voltage-Dependent Sodium Channels
|
Jones, Hannah M.
|
|
2016
|
|
7 |
p. 875-887
|
artikel
|
| 24 |
Clinical Pharmacokinetics and Pharmacodynamics of Albiglutide
|
Brønden, Andreas
|
|
2017
|
|
7 |
p. 719-731
|
artikel
|
| 25 |
Clinical Pharmacokinetics and Pharmacodynamics of Cediranib
|
Tang, Weifeng
|
|
2016
|
|
7 |
p. 689-702
|
artikel
|
| 26 |
Clinical Pharmacokinetics and Pharmacodynamics of Cefepime
|
Pais, Gwendolyn M.
|
|
|
|
7 |
p. 929-953
|
artikel
|
| 27 |
Clinical Pharmacokinetics and Pharmacodynamics of Dasatinib
|
Levêque, Dominique
|
|
|
|
7 |
p. 849-856
|
artikel
|
| 28 |
Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor
|
Kasichayanula, Sreeneeranj
|
|
2018
|
|
7 |
p. 769-779
|
artikel
|
| 29 |
Clinical Pharmacokinetics and Pharmacodynamics of Fostamatinib and Its Active Moiety R406
|
Matsukane, Ryosuke
|
|
|
|
7 |
p. 955-972
|
artikel
|
| 30 |
Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors
|
Centanni, Maddalena
|
|
2019
|
|
7 |
p. 835-857
|
artikel
|
| 31 |
Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors
|
Centanni, Maddalena
|
|
|
|
7 |
p. 835-857
|
artikel
|
| 32 |
Clinical Pharmacokinetics and Pharmacodynamics of Linagliptin
|
Graefe-Mody, Ulrike
|
|
2012
|
|
7 |
p. 411-427
|
artikel
|
| 33 |
Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides
|
al Jalali, Valentin
|
|
2018
|
|
7 |
p. 797-816
|
artikel
|
| 34 |
Clinical Pharmacokinetics of Antibacterials in Cerebrospinal Fluid
|
Di Paolo, Antonello
|
|
2013
|
|
7 |
p. 511-542
|
artikel
|
| 35 |
Clinical Pharmacokinetics of Quetiapine
|
DeVane, C. Lindsay
|
|
|
|
7 |
p. 509-522
|
artikel
|
| 36 |
Combining ‘Bottom-Up’ and ‘Top-Down’ Methods to Assess Ethnic Difference in Clearance: Bitopertin as an Example
|
Feng, Sheng
|
|
2015
|
|
7 |
p. 823-832
|
artikel
|
| 37 |
Comment on: “Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?”
|
Nicolas, Patrick
|
|
|
|
7 |
p. 959-960
|
artikel
|
| 38 |
Comment on “Levothyrox® New and Old Formulations: Are They Switchable for Millions of Patients?”
|
Munafo, Alain
|
|
|
|
7 |
p. 969-971
|
artikel
|
| 39 |
Comment on: “Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?”
|
Coste, Joël
|
|
|
|
7 |
p. 965-966
|
artikel
|
| 40 |
Comment on: Levothyrox® New and Old Formulations: Are They Switchable for Millions of Patients?
|
Tréchot, Philippe
|
|
|
|
7 |
p. 977-978
|
artikel
|
| 41 |
Comment on: “Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?”
|
Nicolas, Patrick
|
|
|
|
7 |
p. 959-960
|
artikel
|
| 42 |
Comment on “Levothyrox® New and Old Formulations: Are They Switchable for Millions of Patients?”
|
Munafo, Alain
|
|
|
|
7 |
p. 969-971
|
artikel
|
| 43 |
Comment on: “Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?”
|
Coste, Joël
|
|
|
|
7 |
p. 965-966
|
artikel
|
| 44 |
Comment on: Levothyrox® New and Old Formulations: Are They Switchable for Millions of Patients?
|
Tréchot, Philippe
|
|
|
|
7 |
p. 977-978
|
artikel
|
| 45 |
Comment on: “Morbidly Obese Patients Exhibit Increased CYP2E1-Mediated Oxidation of Acetaminophen”
|
Reith, David M.
|
|
2018
|
|
7 |
p. 895-896
|
artikel
|
| 46 |
Comment on “Target-Controlled Continuous Infusion for Antibiotic Dosing: Proof-of-Principle in an In-silico Vancomycin Trial in Intensive Care Unit Patients”
|
Minichmayr, Iris K.
|
|
2019
|
|
7 |
p. 981-982
|
artikel
|
| 47 |
Comment on “Target-Controlled Continuous Infusion for Antibiotic Dosing: Proof-of-Principle in an In-silico Vancomycin Trial in Intensive Care Unit Patients”
|
Minichmayr, Iris K.
|
|
|
|
7 |
p. 981-982
|
artikel
|
| 48 |
Comparative Pharmacokinetics and Pharmacodynamics of Platelet Adenosine Diphosphate Receptor Antagonists and their Clinical Implications
|
Floyd, Christopher N.
|
|
2012
|
|
7 |
p. 429-442
|
artikel
|
| 49 |
Comparison of a Novel Formulation of Abiraterone Acetate vs. the Originator Formulation in Healthy Male Subjects: Two Randomized, Open-Label, Crossover Studies
|
Goldwater, Ronald
|
|
2017
|
|
7 |
p. 803-813
|
artikel
|
| 50 |
Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study
|
Dickinson, Laura
|
|
2015
|
|
7 |
p. 861-873
|
artikel
|
| 51 |
Correction to: A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis
|
van Beek, Stijn W.
|
|
|
|
7 |
p. 955
|
artikel
|
| 52 |
Correction to: Clinical Pharmacokinetics and Pharmacodynamics of CSL112
|
Ortega-Paz, Luis
|
|
|
|
7 |
p. 1043
|
artikel
|
| 53 |
Correction to: Effect of Various Dosing Schedules on the Pharmacokinetics of Oral Semaglutide: A Randomised Trial in Healthy Subjects
|
van Hout, Marloes
|
|
|
|
7 |
p. 1045-1047
|
artikel
|
| 54 |
Correction to: Pharmacokinetics, Pharmacodynamics, and Dose Optimization of Cefiderocol during Continuous Renal Replacement Therapy
|
Wenzler, Eric
|
|
|
|
7 |
p. 1069
|
artikel
|
| 55 |
Cost-Neutral Optimization of Pazopanib Exposure by Splitting Intake Moments: A Prospective Pharmacokinetic Study in Cancer Patients
|
Groenland, Stefanie L.
|
|
|
|
7 |
p. 941-948
|
artikel
|
| 56 |
Determining the Effects of Chronic Kidney Disease on Organic Anion Transporter1/3 Activity Through Physiologically Based Pharmacokinetic Modeling
|
Dubinsky, Samuel
|
|
|
|
7 |
p. 997-1012
|
artikel
|
| 57 |
Development of a Physiologically Based Pharmacokinetic Modelling Approach to Predict the Pharmacokinetics of Vancomycin in Critically Ill Septic Patients
|
Radke, Christian
|
|
2016
|
|
7 |
p. 759-779
|
artikel
|
| 58 |
Dose–Exposure–Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD
|
Goulooze, Sebastiaan Camiel
|
|
|
|
7 |
p. 1013-1025
|
artikel
|
| 59 |
Drug Interactions Between Peficitinib, an Orally Administered, Once-Daily Janus Kinase Inhibitor, and Rosuvastatin in Healthy Subjects
|
Zhu, Tong
|
|
2016
|
|
7 |
p. 747-757
|
artikel
|
| 60 |
Drug Interaction Studies with Esomeprazole, the (S)-Isomer of Omeprazole
|
Andersson, Tommy
|
|
|
|
7 |
p. 523-537
|
artikel
|
| 61 |
Effect of Activated Charcoal on Rivaroxaban Complex Absorption
|
Ollier, Edouard
|
|
2016
|
|
7 |
p. 793-801
|
artikel
|
| 62 |
Effect of Hepatic Impairment on the Pharmacokinetics of Pradigastat, a Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitor
|
Hirano, Masaru
|
|
2015
|
|
7 |
p. 761-770
|
artikel
|
| 63 |
Effect of Renal Impairment on the Pharmacokinetics of Pradigastat, a Novel Diacylglycerol Acyltransferase1 (DGAT1) Inhibitor
|
Mita, Sachiko
|
|
2015
|
|
7 |
p. 751-760
|
artikel
|
| 64 |
Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
|
Urva, Shweta
|
|
|
|
7 |
p. 1057-1067
|
artikel
|
| 65 |
Effects of PON1 Gene Promoter DNA Methylation and Genetic Variations on the Clinical Outcomes of Dual Antiplatelet Therapy for Patients Undergoing Percutaneous Coronary Intervention
|
Lei, He-Ping
|
|
2017
|
|
7 |
p. 817-829
|
artikel
|
| 66 |
Elucidating the Plasma and Liver Pharmacokinetics of Simeprevir in Special Populations Using Physiologically Based Pharmacokinetic Modelling
|
Snoeys, Jan
|
|
2016
|
|
7 |
p. 781-792
|
artikel
|
| 67 |
Enzalutamide Reduces Oxycodone Exposure in Men with Prostate Cancer
|
Detert Oude Weme, S. E. H.
|
|
|
|
7 |
p. 989-996
|
artikel
|
| 68 |
Erratum to: A Novel Maturation Function for Clearance of the Cytochrome P450 3A Substrate Midazolam from Preterm Neonates to Adults
|
Ince, Ibrahim
|
|
2013
|
|
7 |
p. 611
|
artikel
|
| 69 |
Erratum to: Prediction of Drug–Drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach
|
Siccardi, Marco
|
|
2013
|
|
7 |
p. 613-614
|
artikel
|
| 70 |
Establishing the Pharmacokinetics of Genetic Vaccines is Essential for Maximising their Safety and Efficacy
|
Naasani, Imad
|
|
|
|
7 |
p. 921-927
|
artikel
|
| 71 |
Estradiol and Spironolactone Plasma Pharmacokinetics Among Brazilian Transgender Women Using HIV Pre-Exposure Prophylaxis: Analysis of Potential Interactions
|
Cattani, Vitória Berg
|
|
|
|
7 |
p. 1031-1041
|
artikel
|
| 72 |
Exposure–Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII
|
Jonsson, Fredrik
|
|
|
|
7 |
p. 931-941
|
artikel
|
| 73 |
Extrapolation of a Brivaracetam Exposure–Response Model from Adults to Children with Focal Seizures
|
Schoemaker, Rik
|
|
2017
|
|
7 |
p. 843-854
|
artikel
|
| 74 |
Glomerular Filtration Rate in Asphyxiated Neonates Under Therapeutic Whole-Body Hypothermia, Quantified by Mannitol Clearance
|
Deferm, Neel
|
|
|
|
7 |
p. 897-906
|
artikel
|
| 75 |
Hyperinflammation Reduces Midazolam Metabolism in Critically Ill Adults with COVID-19
|
Smeets, Tim J. L.
|
|
|
|
7 |
p. 973-983
|
artikel
|
| 76 |
Impact of Ethnicity-Specific Hepatic Microsomal Scaling Factor, Liver Weight, and Cytochrome P450 (CYP) 1A2 Content on Physiologically Based Prediction of CYP1A2-Mediated Pharmacokinetics in Young and Elderly Chinese Adults
|
Li, Guo-Fu
|
|
2019
|
|
7 |
p. 927-941
|
artikel
|
| 77 |
Impact of Ethnicity-Specific Hepatic Microsomal Scaling Factor, Liver Weight, and Cytochrome P450 (CYP) 1A2 Content on Physiologically Based Prediction of CYP1A2-Mediated Pharmacokinetics in Young and Elderly Chinese Adults
|
Li, Guo-Fu
|
|
|
|
7 |
p. 927-941
|
artikel
|
| 78 |
Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature
|
Wolking, Stefan
|
|
2015
|
|
7 |
p. 709-735
|
artikel
|
| 79 |
Impact of Low-Dose Ritonavir on Danoprevir Pharmacokinetics
|
Reddy, Micaela B.
|
|
2012
|
|
7 |
p. 457-465
|
artikel
|
| 80 |
Integration of Placental Transfer in a Fetal–Maternal Physiologically Based Pharmacokinetic Model to Characterize Acetaminophen Exposure and Metabolic Clearance in the Fetus
|
Mian, Paola
|
|
|
|
7 |
p. 911-925
|
artikel
|
| 81 |
Interactions Between Antiepileptic and Antibiotic Drugs: A Systematic Review and Meta-Analysis with Dosing Implications
|
Carnovale, Carla
|
|
2018
|
|
7 |
p. 875-886
|
artikel
|
| 82 |
Interactions Between Antiepileptic and Antibiotic Drugs: A Systematic Review and Meta-Analysis with Dosing Implications
|
Carnovale, Carla
|
|
|
|
7 |
p. 875-886
|
artikel
|
| 83 |
Interspecies Scaling for the Prediction of Drug Clearance in Children
|
Mahmood, Iftekhar
|
|
2010
|
|
7 |
p. 479-492
|
artikel
|
| 84 |
Intraindividual Variability in Absolute Bioavailability and Clearance of Midazolam in Healthy Individuals
|
Kvitne, Kine Eide
|
|
|
|
7 |
p. 981-987
|
artikel
|
| 85 |
Intranasal Fentanyl for Intervention-Associated Breakthrough Pain After Cardiac Surgery
|
Valtola, Antti
|
|
|
|
7 |
p. 907-919
|
artikel
|
| 86 |
Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?
|
Concordet, Didier
|
|
2019
|
|
7 |
p. 827-833
|
artikel
|
| 87 |
Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?
|
Concordet, Didier
|
|
|
|
7 |
p. 827-833
|
artikel
|
| 88 |
Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?
|
Concordet, Didier
|
|
|
|
7 |
p. 827-833
|
artikel
|
| 89 |
Liver Cirrhosis Affects the Pharmacokinetics of the Six Substrates of the Basel PhenotypingCocktail Differently
|
Duthaler, Urs
|
|
|
|
7 |
p. 1039-1055
|
artikel
|
| 90 |
Local versus Systemic Anti-Tumour Necrosis Factor-α Effects of Adalimumab in Rheumatoid Arthritis
|
Stepensky, David
|
|
2012
|
|
7 |
p. 443-455
|
artikel
|
| 91 |
Morbidly Obese Patients Exhibit Increased CYP2E1-Mediated Oxidation of Acetaminophen
|
Rongen, Anne van
|
|
2016
|
|
7 |
p. 833-847
|
artikel
|
| 92 |
Oral Yohimbine as a New Probe Drug to Predict CYP2D6 Activity: Results of a Fixed-Sequence Phase I Trial
|
Vay, Manuela
|
|
|
|
7 |
p. 927-939
|
artikel
|
| 93 |
Paraxanthine/Caffeine Concentration Ratios in Hair: An Alternative for Plasma-Based Phenotyping of Cytochrome P450 1A2?
|
Kesel, Pieter M. M. De
|
|
2015
|
|
7 |
p. 771-781
|
artikel
|
| 94 |
Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes
|
Scheen, André J.
|
|
2016
|
|
7 |
p. 703-718
|
artikel
|
| 95 |
Pharmacokinetic Evidence for Suboptimal Treatment of Adrenal Insufficiency with Currently Available Hydrocortisone Tablets
|
Simon, Nicolas
|
|
2010
|
|
7 |
p. 455-463
|
artikel
|
| 96 |
Pharmacokinetic Modeling, Simulation, and Development of a Limited Sampling Strategy of Cycloserine in Patients with Multidrug-/Extensively Drug-Resistant Tuberculosis
|
van der Galiën, Ruben
|
|
|
|
7 |
p. 899-910
|
artikel
|
| 97 |
Pharmacokinetic Modelling of the Plasma Protein Binding of Mycophenolic Acid in Renal Transplant Recipients
|
Hest, Reinier M. van
|
|
2009
|
|
7 |
p. 463-476
|
artikel
|
| 98 |
Pharmacokinetic Optimization of Immunosuppressive Therapy in Thoracic Transplantation: Part I
|
Monchaud, Caroline
|
|
2009
|
|
7 |
p. 419-462
|
artikel
|
| 99 |
Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir
|
Kirby, Brian J.
|
|
2015
|
|
7 |
p. 677-690
|
artikel
|
| 100 |
Pharmacokinetic/Pharmacodynamic Modelling of Receptor Internalization with CRTH2 Antagonists to Optimize Dose Selection
|
Krause, Andreas
|
|
2015
|
|
7 |
p. 813-821
|
artikel
|
| 101 |
Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine
|
Hodge, Daryl
|
|
|
|
7 |
p. 835-853
|
artikel
|
| 102 |
Pharmacokinetics and Pharmacodynamics of Antibacterials, Antifungals, and Antivirals Used Most Frequently in Neonates and Infants
|
Roberts, Jessica K.
|
|
2014
|
|
7 |
p. 581-610
|
artikel
|
| 103 |
Pharmacokinetics of Antiretrovirals in Genital Secretions and Anatomic Sites of HIV Transmission: Implications for HIV Prevention
|
Trezza, Christine R.
|
|
2014
|
|
7 |
p. 611-624
|
artikel
|
| 104 |
Pharmacokinetics of Cannabis in Cancer Cachexia-Anorexia Syndrome
|
Reuter, Stephanie E.
|
|
2016
|
|
7 |
p. 807-812
|
artikel
|
| 105 |
Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
|
Scheen, André J.
|
|
2015
|
|
7 |
p. 691-708
|
artikel
|
| 106 |
Pharmacokinetic Variability of Therapeutic Antibodies in Humans: A Comprehensive Review of Population Pharmacokinetic Modeling Publications
|
Bensalem, Amina
|
|
|
|
7 |
p. 857-874
|
artikel
|
| 107 |
Pharmacological Issues of Linezolid
|
Paolo, Antonello Di
|
|
2010
|
|
7 |
p. 439-447
|
artikel
|
| 108 |
Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab
|
Wijnsma, Kioa Lente
|
|
2019
|
|
7 |
p. 859-874
|
artikel
|
| 109 |
Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab
|
Wijnsma, Kioa Lente
|
|
|
|
7 |
p. 859-874
|
artikel
|
| 110 |
Physiologically Based Pharmacokinetic Modeling for Trimethoprim and Sulfamethoxazole in Children
|
Thompson, Elizabeth J.
|
|
2019
|
|
7 |
p. 887-898
|
artikel
|
| 111 |
Physiologically Based Pharmacokinetic Modeling for Trimethoprim and Sulfamethoxazole in Children
|
Thompson, Elizabeth J.
|
|
|
|
7 |
p. 887-898
|
artikel
|
| 112 |
Physiologically Based Pharmacokinetic Modelling of Hyperforin to Predict Drug Interactions with St John’s Wort
|
Adiwidjaja, Jeffry
|
|
2019
|
|
7 |
p. 911-926
|
artikel
|
| 113 |
Physiologically Based Pharmacokinetic Modelling of Hyperforin to Predict Drug Interactions with St John’s Wort
|
Adiwidjaja, Jeffry
|
|
|
|
7 |
p. 911-926
|
artikel
|
| 114 |
Piperacillin-Tazobactam in Intensive Care Units: A Review of Population Pharmacokinetic Analyses
|
El-Haffaf, Ibrahim
|
|
|
|
7 |
p. 855-875
|
artikel
|
| 115 |
Population Pharmacokinetic Modeling of Benralizumab in Adult and Adolescent Patients with Asthma
|
Yan, Li
|
|
2019
|
|
7 |
p. 943-958
|
artikel
|
| 116 |
Population Pharmacokinetic Modeling of Benralizumab in Adult and Adolescent Patients with Asthma
|
Yan, Li
|
|
|
|
7 |
p. 943-958
|
artikel
|
| 117 |
Population Pharmacokinetic Modeling of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol in Patients with Asthma, Using Data from a Phase IIIA Study (CAPTAIN)
|
Yang, Shuying
|
|
|
|
7 |
p. 887-896
|
artikel
|
| 118 |
Population Pharmacokinetic Model of Intravenous Busulfan in Hematopoietic Cell Transplantation: Systematic Review and Comparative Simulations
|
Takahashi, Takuto
|
|
|
|
7 |
p. 955-968
|
artikel
|
| 119 |
Population Pharmacokinetic Model to Optimize Cefotaxime Dosing Regimen in Critically Ill Children
|
Béranger, Agathe
|
|
2017
|
|
7 |
p. 867-875
|
artikel
|
| 120 |
Population Pharmacokinetic/Pharmacodynamic Modelling of Dipeptidyl Peptidase IV Inhibitors
|
Landersdorfer, Cornelia B.
|
|
2015
|
|
7 |
p. 673-675
|
artikel
|
| 121 |
Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus
|
Retlich, Silke
|
|
2015
|
|
7 |
p. 737-750
|
artikel
|
| 122 |
Population Pharmacokinetics and Pharmacogenetics of Everolimus in Renal Transplant Patients
|
Moes, Dirk Jan A. R.
|
|
2012
|
|
7 |
p. 467-480
|
artikel
|
| 123 |
Population Pharmacokinetics of Imipenem in Critically Ill Patients: A Parametric and Nonparametric Model Converge on CKD-EPI Estimated Glomerular Filtration Rate as an Impactful Covariate
|
de Velde, Femke
|
|
|
|
7 |
p. 885-898
|
artikel
|
| 124 |
Population Pharmacokinetics of Inhaled Umeclidinium and Vilanterol in Patients with Chronic Obstructive Pulmonary Disease
|
Goyal, Navin
|
|
2014
|
|
7 |
p. 637-648
|
artikel
|
| 125 |
Population Pharmacokinetics of MCLA-128, a HER2/HER3 Bispecific Monoclonal Antibody, in Patients with Solid Tumors
|
de Vries Schultink, Aurelia H. M.
|
|
|
|
7 |
p. 875-884
|
artikel
|
| 126 |
Population Pharmacokinetics of Oral Risperidone in Children, Adolescents and Adults with Psychiatric Disorders
|
Thyssen, An
|
|
2010
|
|
7 |
p. 465-478
|
artikel
|
| 127 |
Population Pharmacokinetics of Posaconazole in Immune-Compromised Children and Assessment of Target Attainment in Invasive Fungal Disease
|
McCann, Sean
|
|
|
|
7 |
p. 997-1009
|
artikel
|
| 128 |
Population Pharmacokinetics of Subcutaneous Pasireotide in Healthy Volunteers and Cushing’s Disease Patients
|
Nedelman, Jerry
|
|
2017
|
|
7 |
p. 855-866
|
artikel
|
| 129 |
Population Pharmacokinetics/Pharmacodynamics of Erlotinib and Pharmacogenomic Analysis of Plasma and Cerebrospinal Fluid Drug Concentrations in Japanese Patients with Non-Small Cell Lung Cancer
|
Fukudo, Masahide
|
|
2013
|
|
7 |
p. 593-609
|
artikel
|
| 130 |
Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics
|
Gill, Katherine L.
|
|
2016
|
|
7 |
p. 789-805
|
artikel
|
| 131 |
Predicting Chemotherapy Distribution into Breast Milk for Breastfeeding Women Using a Population Pharmacokinetic Approach
|
Damoiseaux, David
|
|
|
|
7 |
p. 969-980
|
artikel
|
| 132 |
Prediction of drug-drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach
|
Siccardi, Marco
|
|
2013
|
|
7 |
p. 583-592
|
artikel
|
| 133 |
Prediction of Free from Total Mycophenolic Acid Concentrations in Stable Renal Transplant Patients: A Population-Based Approach
|
Colom, Helena
|
|
2017
|
|
7 |
p. 877-893
|
artikel
|
| 134 |
Prediction of Warfarin Maintenance Dose in Han Chinese Patients Using a Mechanistic Model Based on Genetic and Non-Genetic Factors
|
Lu, Yuan
|
|
2013
|
|
7 |
p. 567-581
|
artikel
|
| 135 |
Predictive Performance of Pharmacokinetic Model-Based Virtual Trials of Vancomycin in Neonates: Mathematics Matches Clinical Observation
|
Yao, Bu-Fan
|
|
|
|
7 |
p. 1027-1038
|
artikel
|
| 136 |
Propofol Breath Monitoring as a Potential Tool to Improve the Prediction of Intraoperative Plasma Concentrations
|
Colin, Pieter
|
|
2015
|
|
7 |
p. 849-859
|
artikel
|
| 137 |
Rate and Extent of Drug Accumulation after Multiple Dosing Revisited
|
Brocks, Dion R.
|
|
2010
|
|
7 |
p. 421-438
|
artikel
|
| 138 |
Refinement of the Population Pharmacokinetic Model for the Monoclonal Antibody Matuzumab
|
Kuester, Katharina
|
|
2009
|
|
7 |
p. 477-487
|
artikel
|
| 139 |
Reporting Guidelines for Clinical Pharmacokinetic Studies: The ClinPK Statement
|
Kanji, Salmaan
|
|
2015
|
|
7 |
p. 783-795
|
artikel
|
| 140 |
Semi-Mechanistic Model for Predicting the Dosing Rate in Children and Neonates for Drugs Mainly Eliminated by Cytochrome Metabolism
|
Cerruti, Lena
|
|
2017
|
|
7 |
p. 831-841
|
artikel
|
| 141 |
Simultaneous Pharmacogenetics-Based Population Pharmacokinetic Analysis of Darunavir and Ritonavir in HIV-Infected Patients
|
Moltó, José
|
|
2013
|
|
7 |
p. 543-553
|
artikel
|
| 142 |
Single- and Multiple-Dose Milnacipran Pharmacokinetics in Healthy Han Chinese Volunteers
|
Ruan, Can-Jun
|
|
2015
|
|
7 |
p. 889-896
|
artikel
|
| 143 |
Steady-State Pharmacokinetics and Tolerability of Trans-Resveratrol 2000mg Twice Daily with Food, Quercetin and Alcohol (Ethanol) in Healthy Human Subjects
|
Porte, Charles la
|
|
2010
|
|
7 |
p. 449-454
|
artikel
|
| 144 |
Systemic and Target-Site Pharmacokinetics of Antiparasitic Agents
|
al Jalali, Valentin
|
|
|
|
7 |
p. 827-847
|
artikel
|
| 145 |
Telaprevir: Clinical Pharmacokinetics, Pharmacodynamics, and Drug–Drug Interactions
|
Kiang, Tony K. L.
|
|
|
|
7 |
p. 487-510
|
artikel
|
| 146 |
Telaprevir: Clinical Pharmacokinetics, Pharmacodynamics, and Drug–Drug Interactions
|
Kiang, Tony K. L.
|
|
2013
|
|
7 |
p. 487-510
|
artikel
|
| 147 |
The Effect of Renal Impairment on the Pharmacokinetics and Safety of Talazoparib in Patients with Advanced Solid Tumors
|
Durairaj, Chandrasekar
|
|
|
|
7 |
p. 921-930
|
artikel
|
| 148 |
The Pharmacokinetics and Pharmacodynamics of TOL101, a Murine IgM Anti-Human αβ T Cell Receptor Antibody, in Renal Transplant Patients
|
Getts, Daniel R.
|
|
2014
|
|
7 |
p. 649-657
|
artikel
|
| 149 |
The Pharmacokinetics and Pharmacodynamics of TOL101, a Murine IgM Anti-Human αβ T Cell Receptor Antibody, in Renal Transplant Patients
|
Getts, Daniel R.
|
|
|
|
7 |
p. 649-657
|
artikel
|
| 150 |
The Population Pharmacokinetics of High-Dose Methotrexate in Infants with Acute Lymphoblastic Leukemia Highlight the Need for Bedside Individualized Dose Adjustment: A Report from the Children’s Oncology Group
|
Beechinor, Ryan J.
|
|
2019
|
|
7 |
p. 899-910
|
artikel
|
| 151 |
The Population Pharmacokinetics of High-Dose Methotrexate in Infants with Acute Lymphoblastic Leukemia Highlight the Need for Bedside Individualized Dose Adjustment: A Report from the Children’s Oncology Group
|
Beechinor, Ryan J.
|
|
|
|
7 |
p. 899-910
|
artikel
|
| 152 |
Tyrosine Kinase Inhibitors and Proton Pump Inhibitors: An Evaluation of Treatment Options
|
Leeuwen, Roelof W. F. van
|
|
2017
|
|
7 |
p. 683-688
|
artikel
|
Tijdschrift beschrijving